Invention Application
![CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF](/docs/US/2022-05-12/US20220144846A1/abs.jpg.600x600.jpg)
- Patent Title: CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF
-
Application No.: US17430373Application Date: 2020-02-12
-
Publication No.: US20220144846A1Publication Date: 2022-05-12
- Inventor: Xiaojing YANG , Amanda Patrice Surajhie SAMUEL
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- International Application: PCT/IB2020/051128 WO 20200212
- Main IPC: C07D487/08
- IPC: C07D487/08
![CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF](/abs-image/US/2022/05/12/US20220144846A1/abs.jpg.150x150.jpg)
Abstract:
The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof.
Information query
